Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | INCA035784 |
| Synonyms | |
| Therapy Description |
INCA035784 is a bispecific antibody targeting CD3 and mutant CALR, which potentially induces cytotoxicity against CD34+ tumor cells harboring CALR mutations (HemaSphere, 9(S1), S212). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| INCA035784 | INCA-035784|INCA 035784 | CD3 Antibody 119 | INCA035784 is a bispecific antibody targeting CD3 and mutant CALR, which potentially induces cytotoxicity against CD34+ tumor cells harboring CALR mutations (HemaSphere, 9(S1), S212). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07008118 | Phase I | INCA035784 | A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms | Recruiting | USA | AUS | 0 |